Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.
Journal: Journal for immunotherapy of cancer
Published: July 11, 2021
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
Journal: CA: a cancer journal for clinicians
Published: June 16, 2020
Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy.
Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy.
Journal: Cancer genomics & proteomics
Published: January 22, 2020
Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?
Journal: Journal of thoracic disease
Published: May 01, 2018
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 07, 2018
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
Journal: Cancer discovery
Published: April 12, 2017
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: November 16, 2016
The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.
Journal: Future oncology (London, England)
Published: May 12, 2016
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
Journal: Nature communications
Published: February 04, 2016
Last Updated: 09/26/2026